|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2018加拿大心境障碍与焦虑障碍治疗协作组/国际双相障碍学会指南:双相障碍的管理显示文摘加拿大心境障碍与焦虑障碍治疗协作组(Canadian Network for Mood and Anxiety Treatments,CANMAT)曾于2005年发布了第1版双相障碍管理指南,并分别于2007、2009和2013年对该指南进行了更新,其中最近的2次更新是与国际双相障碍学会(International Society for Bipolar Disorders,ISBD)合作完成。2018版CANMAT/ISBD双相障碍治疗指南(以下简称指南)反映了自2005年首版指南发表以来本领域取得的重大进展,包括疾病诊断与疾病管理的更新以及药物治疗与心理治疗的近期研究进展。这些前沿进展中综合考虑了循证证据的级别,并基于治疗疗效、临床实践经验、安全性、耐受性和药物导致的转相风险等,对一线、二线及三线治疗方案进行了简明而清晰的推荐。本指南中新增内容涵盖了双相Ⅰ型障碍(BD-Ⅰ)的躁狂发作急性期、抑郁发作急性期和双相障碍维持期的一线及二线治疗推荐等级划分。这种对治疗推荐等级的划分综合考虑了治疗方法对双相障碍不同时相的影响,将进一步帮助临床医生做出基于循证证据的治疗决策。锂盐、喹硫平、双丙戊酸盐、阿塞那平、阿立哌唑、帕利哌酮、利培酮和卡利拉嗪单药或联合使用被推荐为躁狂发作急性期的一线治疗选择。BD-Ⅰ抑郁期的一线治疗选择包括喹硫平、鲁拉西酮、锂盐、拉莫三嗪单药,鲁拉西酮联合锂盐或双丙戊酸盐或拉莫三嗪辅助治疗。尽管急性期治疗有效的药物通常应继续用于BD-Ⅰ的维持期治疗,但也存在一些特殊情况(例如抗抑郁药)。现有数据表明,锂盐、喹硫平、双丙戊酸盐、拉莫三嗪、阿塞那平和阿立哌唑单药或联合治疗应被视为维持治疗的初始或更换治疗方案时的一线选择。除了探讨BD-Ⅰ的相关问题外,本指南中还对双相Ⅱ型障碍(BD-Ⅱ)的临床管理进行了系统回顾并给予治疗推荐,同时针对特殊人群也有相关推荐,如处于各个生殖周期的女性、儿童、青少年和老年人。此外,本指南中还讨论了特定精神疾病及共病(如物质滥用、焦虑障碍和代谢性疾病)的影响。最后,本指南中概述了安全性和药物监测的相关问题。CANMAT/ISBD工作组希望本指南能够成为全球临床医生的实用工具。 | Lakshmi N Yatham Sidney H Kennedy Sagar V Parikh Ayal Sehaffer David J Bond Benicio N Frey Verinder Sharma Benjamin I Goldstein Soham Rej Serge Beaulieu Martin Alda Glenda MaeQueen Roumen V Milev Arun Ravindran Claire O'Donovan Diane Mclntosh Raymond W Lam Gustavo Vazquez Flavio Kapczinski Roger S Melntyre Jan Kozicky Shigenobu Kanba Beny Lafer Trisha Suppes Joseph R Calabrese Eduard Vieta Gin Malhi Robert M Post Michael Berk 胡晨(译) 王刚(译) | 2019 | 中华精神科杂志2019，52，1： | 25 |
| 2 | The effect of vaccination against Porcine reproductive and respiratory syndrome virus (PRRSV) on the Porcine circo- virus-2 (PCV-2) load in porcine circovirus associated disease (PCVAD) affected pigs显示文摘 | Genzow Marika/M Schwartz Kent/K Gonzalez Glenda/G | 2009 | Can J Vet Res2009，3，2： | 1 |
| 3 | Synergistic accumulationof iron and zinc by cultured astrocytes显示文摘 | GLENDA M BISHOP I F SCHEIBER R D | 2010 | Journal of Neural Transmission2010，117，7： | 1 |
| 4 | Macroautophagy in sporadic and the genetic form of Parkinson’s disease with the A53T asynuclein mutation显示文摘Background:The A53T mutation in the a-synuclein gene causes autosomal-dominant Lewy body Parkinson’s disease(PD).Cultured cell models have linked this mutation to increased cell macroautophagy,although evidence of enhanced macroautophagy in patients with this mutation has not been assessed.Objective:To determine whether macroautophagy is increased by the A53T a-synuclein gene mutation in PD patients and cell models.Methods:Formalin-fixed paraffin-embedded 10μm-thick tissue sections from the substantia nigra and anterior cingulate cortex of two PD patients with the A53T a-synuclein gene mutation were compared with four sporadic PD cases and four controls obtained from the Sydney Brain Bank.Lewy bodies were isolated from frontal cortex of a case with late stage PD(recruited from South Australian Brain Bank).Immunohistochemistry was performed for a-synuclein and the macroautophagy markers autophagy-specific gene(ATG)5,ATG6/Beclin1 and ATG8/LC3.SHSY5Y cells were transfected with wild type or A53T mutant a-synuclein plasmids and observable changes in macroautophagy marker protein levels assessed using Western blotting.Results:a-Synuclein immunoreactive neurites and dots were more numerous in patients with A53T mutations compared with late stage sporadic PD patients,and perinuclear cytoplasmic a-synuclein aggregates were observed in the a-synuclein A53T gene transfected SH-SY5Y cells compared to wild type transfections.All PD patients(with or without A53T mutations)had increased immunohistochemical evidence for macroautophagy compared with controls,and the levels of the ATG5 complex were equally increased in wild type and A53T a-synuclein gene transfected cells compared to controls.Conclusion:Despite increased a-synuclein accumulation with A53T mutations,macroautophagy is not increased above that observed in sporadic patients with PD or in cells transfected with wild type a-synuclein,suggesting that mutated a-synuclein protein is not removed by macroautophagy. | Yue Huang Fariba Chegini Germaine Chua Karen Murphy Weiping Gai Glenda M Halliday | 2012 | Translational Neurodegeneration2012，1，1： | 1 |
| 5 | Reliability of HSP70(HSPA)expression as a prognostic marker in glioma显示文摘 | Beaman G M Dennison S R Chatfield L K Glenda Maria B Dennison S R Chatfield L K | 2014 | Molecular&Cellular Biochemistry2014，393，1： | 1 |
| 6 | Educational prepa- ration for clinical nursing: The satisfaction of students and new graduates from two Australian universities显示文摘 | Kathleen M Patricial K Glenda P | 2014 | Nurse Edueation Today2014，34，4： | 1 |
| 7 | HOXA6: A Novel Candidate Gene in AML显示文摘 | Glenda M Damian F Mary M | 2006 | Blood2006，108，11： | 1 |
| 8 | Developing Zones of Tolerance for Managing Pas- senger Rail Service Quality显示文摘 | ROBERT Y CAVANA LAWRENCE M CORBETT Y L (GLENDA) LO | 2007 | International Journal of Quality & Reliability Management2007，24，1： | 1 |
| 9 | Integrin-mediated type II TGF-[Beta] receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling显示文摘 | Chen Xiwu Wang Hongtao Liao Hong-Jun Hu Wen Gewin Leslie Mernaugh Glenda Zhang Sheng Zhang Zhong-Yin Vega-Montoto Lorenzo Vanacore Roberto M F?ssler Reinhard Zent Roy Pozzi Ambra | 2014 | Journal of Clinical Investigation2014，，： | 1 |
| 10 | Benefits and risks of self-medication显示文摘 | Carnel M· Hughes James C · McElnay Glenda F · Fleming | 2001 | Drug Safety2001，24，14： | 1 |
| 11 | Data Collection and Analysis of Moisture and Soil Strength Information for Validation of New State-of-the-Ground Models 显示文摘 | GEORGE L M DENNIS W M GLENDA M B | 2003 | Geotechnical and Structures Laboratory2003，，9： | 1 |
| 12 | Developing zones of tolerance for managing passenger rail service quality显示文摘 | Carana R Y Corbett L M (Glenda) Lo Y L | 2007 | International Journal of Quality and Reliability Management2007，24，1： | 1 |
| 13 | Synergistic accumulation of iron and zinc by cultured astrocytes显示文摘 | Glenda M B Ivo F S Ralf D | 2010 | Journal of Neural Transmission2010，117，7： | 1 |
| 14 | The phase 2b HVTN 503/Phambili study test-of-concept HIV vaccine study, investigating a recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblind- ed, long-term follow-up显示文摘 | Glenda E Gray Zoe Moodie Barbara Metch M S | 2014 | Lancet Infect Dis2014，14，5： | 1 |
| 15 | Developing zones of tolerance for managing passenger rail service quality显示文摘 | CAVANA R Y CORBETT L M LO Y L (Glenda) | | 0，，01： | 1 |
| 16 | Aβas a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease显示文摘 | Stephen R R Glenda M B | 2002 | Neurobiology of Aging2002，23，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员